Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) pipeline Target constitutes close to 14 molecules. The latest report Integrin Beta 7 - Drugs In Development, 2022, outlays comprehensive information on the Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Integrin beta-7 is an integrin protein encoded by the ITGB7 gene. It interacts with the cell surface adhesion molecules MADCAM1 which is normally expressed by the vascular endothelium of the gastrointestinal tract. Interactions involve the tripeptide L-D-T in MADCAM1, and L-D-V in fibronectin. It binds to HIV-1 gp120 that allows the virus to enter GALT (major trigger of AIDS disease). The molecules developed by companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 4, 5 and 3 respectively. Report covers products from therapy areas Gastrointestinal, Immunology and Infectious Disease which include indications Inflammatory Bowel Disease, Crohn's Disease (Regional Enteritis), Ulcerative Colitis, Pouchitis, Celiac Disease, Eosinophilic Esophagitis, Graft Versus Host Disease (GVHD), Human Immunodeficiency Virus (HIV) Infections (AIDS) and Unspecified Gastrointestinal Disorders.

Furthermore, this report also reviews key players involved in Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

• The report provides a snapshot of the global therapeutic landscape for Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7)
• The report reviews Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics and enlists all their major and minor projects
• The report assesses Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7)Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope